Form 4: Rigel Pharmaceuticals EVP, Chief Medical Officer Lisa Rojkjaer Reports Stock Option Grant

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reports the grant of a stock option for 9,375 shares after a performance metric was met.

Summary

• Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reported a transaction on March 17, 2025, related to a stock option.
• The stock option, granted on March 27, 2024, covers 9,375 shares of Rigel's common stock, adjusted for a one-for-ten reverse stock split.
• The exercise price is $14.90 per share, which was the closing price on the grant date, adjusted for the reverse stock split.
• The option had a performance-based vesting condition that was met on March 17, 2025, making the grant reportable under Section 16.
• The option is fully vested as of March 17, 2025, the date the performance metric was satisfied.
• Raymond Furey, acting as Attorney-in-Fact, signed the report on March 19, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock options, indicating a neutral sentiment.

Positives

• The vesting of the stock option indicates that a performance metric was successfully achieved.

Industry Context

This filing is a routine disclosure related to executive compensation and is required by the SEC to ensure transparency in insider trading.

Stakeholder Impact

• The vesting of stock options can have a minor positive impact on employee morale.

Key Dates

Keywords

stock option, Rigel Pharmaceuticals, Form 4, insider trading, executive compensation, Rojkjaer, RIGL